Sai Hong Ignatius Ou

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi Heart rate decrease during crizotinib treatment and potential correlation to clinical response
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA
    Cancer 119:1969-75. 2013
  2. doi Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 6:2135-7. 2011
  3. pmc Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868, USA
    Oncologist 17:1351-75. 2012
  4. doi ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 12:447-56. 2012
  5. doi Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 City Drive, Building 56, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 12:151-62. 2012
  6. pmc Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Drug Des Devel Ther 5:471-85. 2011
  7. doi Rare subtypes of adenocarcinoma of the lung
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 City Drive, Building 56, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 11:1535-42. 2011
  8. doi Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 6:942-6. 2011
  9. doi Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California, Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 5:420-7. 2010
  10. doi A comparison study of clinicopathologic characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) patients by smoking status
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 5:158-68. 2010

Detail Information

Publications31

  1. doi Heart rate decrease during crizotinib treatment and potential correlation to clinical response
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA
    Cancer 119:1969-75. 2013
    ..We investigated the frequency and timing of SB, patient characteristics associated with SB during crizotinib treatment, and potential correlation between heart rate (HR) changes and clinical response to crizotinib...
  2. doi Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 6:2135-7. 2011
    ..Herein, we describe the clinical characteristics of three separate patients enrolled in the A8081001 trial (NCT00585195) who developed asymptomatic profound sinus bradycardia with their accompanying electrocardiogram tracings...
  3. pmc Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868, USA
    Oncologist 17:1351-75. 2012
    ....
  4. doi ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 12:447-56. 2012
    ..The next few years should witness a rapid pace of clinical research in ROS1-rearranged tumors utilizing available ALK inhibitors...
  5. doi Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 City Drive, Building 56, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 12:151-62. 2012
    ..It took an unprecedented rapid 4 years from the publication of the discovery of ALK-rearranged NSCLC in August 2007 to the conditional approval of crizotinib in August 2011...
  6. pmc Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Drug Des Devel Ther 5:471-85. 2011
    ..It took an unprecedented four years from the discovery of ALK rearrangement in NSCLC to the approval of crizotinib, the first ever ALK inhibitor, for the treatment of ALK-rearranged NSCLC...
  7. doi Rare subtypes of adenocarcinoma of the lung
    Sai Hong Ignatius Ou
    Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 City Drive, Building 56, Orange, CA 92868, USA
    Expert Rev Anticancer Ther 11:1535-42. 2011
    ..Rare variants of invasive adenocarcinoma of the lung will only now be classified from resection specimens where adequate architecture of tumor can be identified...
  8. doi Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 6:942-6. 2011
    ..Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor...
  9. doi Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California, Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 5:420-7. 2010
    ..We investigated the clinicopathologic features and survival outcome of primary signet-ring carcinoma (SRC) of the lung with comparison to adenocarcinoma of the lung...
  10. doi A comparison study of clinicopathologic characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) patients by smoking status
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 5:158-68. 2010
    ..However, Asian ethnicity represents a diverse and heterogeneous population. In this report, we compared the clinicopathologic characteristics of Asian American NSCLC patient subgroups by smoking status...
  11. doi Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, USA
    J Thorac Oncol 4:1202-11. 2009
    ..We investigated whether the distribution of carcinoma NOS (not otherwise specified) among NSCLC cases in California have changed over time and determined the prognostic significance of carcinoma NOS...
  12. doi Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Irvine Medical Center, Orange, California 92868 3298, USA
    J Thorac Oncol 4:1083-93. 2009
    ..Many Asian NSCLC patients were never-smokers, and never-smokers had improved survival than ever-smokers. We investigated whether Asian ethnicity is a favorable prognostic factor independent of smoking status...
  13. ncbi The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868 3298, USA
    J Thorac Oncol 4:300-10. 2009
    ..We examined the impact of the proposed Internal Association for the Study of Lung Cancer (IASLC) tumor, node, metastasis (TNM) and stage grouping revisions on staging and survival outcome of small cell lung cancer (SCLC)...
  14. ncbi Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology
    S Hi Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, School of Medicine, University of California, Irvine, USA
    Ann Oncol 18:29-35. 2007
    ..This study examined potential survival differences among nasopharyngeal carcinoma (NPC) patients from various ethnicities in the United States...
  15. ncbi Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003
    S H Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, Orange, California 92868, USA
    Cancer 110:1532-41. 2007
    ....
  16. ncbi Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868 3298, USA
    Chest 133:662-9. 2008
    ..The T2 descriptor for staging non-small cell lung cancer (NSCLC) contains several non-size-based criteria. It remains unknown whether the prognostic significance of these non-size-based criteria is dependent on tumor size...
  17. doi Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868 3298, USA
    J Thorac Oncol 3:880-6. 2008
    ..We investigated whether the number of lymph nodes removed influences survival in stage IA NSCLC patients who underwent lobectomy...
  18. doi Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, California, USA
    J Thorac Oncol 4:37-43. 2009
    ....
  19. doi Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Irvine Medical Center, Orange, California 92868, USA
    J Thorac Oncol 3:216-27. 2008
    ....
  20. doi Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era
    Myung Ju Ahn
    Division of Hematology Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 The City Drive, Bldg 56, Rt 81, Rm 241, Orange, CA 92868, USA
    J Thorac Oncol 5:1185-96. 2010
    ..We have previously demonstrated, using a regional California Cancer Registry database, that Asian ethnicity is an independent favorable prognostic factor for overall survival (OS) in non-small cell lung cancer (NSCLC)...
  21. pmc ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 19:4273-81. 2013
    ..Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naïve and crizotinib-resistant cancers...
  22. ncbi Natural history of stage I non-small cell lung cancer: implications for early detection
    Dan J Raz
    University of California, San Francisco, 513 Parnassus Ave, S 321, San Francisco, CA 94131, USA
    Chest 132:193-9. 2007
    ..Our hypothesis is that long-term survival in patients with untreated stage I non-small cell lung cancer (NSCLC) is uncommon...
  23. pmc Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:2383-90. 2013
    ..The detailed etiology of the effect, its symptomatic significance, and the effectiveness of subsequent testosterone replacement have not been previously reported...
  24. doi Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status
    S H Ignatius Ou
    Chao Family Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868 3298, USA
    Cancer 112:2011-20. 2008
    ..In this study, the authors investigated the role of SES in this survival disparity among patients with stage I NSCLC...
  25. ncbi Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors
    Jason A Zell
    The Chao Family Comprehensive Cancer Center, Division of Hematology, Department of Medicine, University of California, Irvine, CA, USA
    J Clin Oncol 23:8396-405. 2005
    ..Classification changes for bronchioloalveolar carcinoma (BAC) by the WHO in May 1999 narrowed its definition. This study was undertaken in an attempt to characterize the impact of these changes on the epidemiology of BAC...
  26. ncbi Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules
    Jason A Zell
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Irvine, California 92697, USA
    Cancer 112:136-43. 2008
    ..However, it is not known whether these differences are observed in patients with non-BAC NSCLC...
  27. doi Identification of ROS1 rearrangement in gastric adenocarcinoma
    Jeeyun Lee
    Department of Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Cancer 119:1627-35. 2013
    ..There is a need for the discovery of additional novel targets in GC...
  28. doi Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence
    Sai Hong Ignatius Ou
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Building 56, Room 241, RT81, Orange, CA 92868, USA
    Crit Rev Oncol Hematol 83:407-21. 2012
    ....
  29. ncbi Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe
    Sai Hong Ignatius Ou
    Division of Hematology Oncology, University of California, Irvine, Orange, California, USA
    Drugs 67:611-2. 2007
  30. ncbi The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer
    Justin F Gainor
    Departments of Medicine, Neurosurgery, Massachusetts General Hospital Cancer Center, Boston, Massachusetts and Department of Medicine, University of California, Irvine, Orange, California
    J Thorac Oncol 8:1570-3. 2013
    ....